Drug maker Pfizer Ltd today said the company's shareholders have approved the sale of its animal health division to its subsidiary, Pfizer Animal Pharma, for Rs 440 crore.
The shareholders of the company have by postal ballot approved the sale with requisite majority on March 26, 2012, Pfizer said in a filing to the BSE.
"The sale of the company's animal health business to Pfizer Animal Pharma Pvt Ltd (PAPPL) has been closed and completed today for a consideration of Rs 440 crore," it added.
Consequent to the closing of the transaction the animal health business comprising marketing and trading in drugs, formulations and vaccines, together with their rights, title and interest in the movable intangible and current assets stand transferred to PAPPL, it said.
The company's board had in February approved the sale of the animal health division by way of slump sale.
Shares of Pfizer were trading at Rs 1,241.60 on the BSE in the afternoon trade, up 3.51% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app